Péptido Natriurético tipo B. Utilidad clÃnica
Palabras clave:
péptidos natriuréticos, BNP, NT-proBNP, insuficiencia cardíacaResumen
El fragmento amino terminal del propéptido tipo B (NT-proBNP), entre los péptidos natriuréticos, es un biomarcador reconocido de fallo cardÃaco; constituye un predictor de muerte y eventos cardiovasculares. Se precisan aspectos relacionados con el péptido natriurético ventricular y su valor como herramienta diagnóstica y pronóstica en la insuficiencia cardÃaca y de sus complicaciones, a través del empleo de algoritmos diagnósticos y los valores de cortes establecidos para estos péptidos de acorde a los grupos etarios. Se realizó revisión amplia de artÃculos disponibles en bases de datos del Medline seleccionándose los relacionados a los péptidos natriuréticos y a su utilidad diagnóstica y pronóstica. El BNP y el NT-proBNP son de gran valor para el diagnóstico del fallo cardÃaco y pronóstico de sus complicaciones, de tal modo permite la exclusión de insuficiencia cardÃaca en pacientes con disnea aguda, siendo importante los valores de cortes para la población general y por grupos de edades.Descargas
Citas
Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. The Eur Journal of Heart Failure. 2004;6:261-68.
Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med. 1999;134:437-44..
Palmer CS, Yandle TG, Nicholls G, Frampton CM, Richards AM. Regional clearance of NT-proBNP from human plasma. Eur J Heart Fail. 2009;11:832-39.
Koolman J, Roehm KH. Color Atlas of Biochemistry. 2nd ed. New York: Thieme Stuttgart; 2005.
Semenov AG, Tamm NN, Seferian KR, Postnikov AB, Karpova NS, Serebryanaya DV, Koshkina EV, Krasnoselsky MI, Katrukha AG. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem. 2010;56:1166-76.
De Bold AJ, Boerenstein HB, Veress AT. A rapid and potent natriuretic response to intravenous injection of atrial extracts in rats. Life Sci. 1981;28:89-94.
De Bold AJ. Atrial Natriuretic Factor: A Hormone Produced by the Heart. Science. 1985;230:767-70.
Task Force Members of the European Society of Cardiology. European Society of Cardiology Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart Journal. 2010;31:2915-57.
Prontera C, Zucchelli GC, Vittorini S, Storti S, Emdin M, Clerico A. Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP. Clin Chim Acta. 2009;400:70-3.
Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55:2062-76.
Rosenberg J, Schou M, Gustafsson F, Badskjær J, Hildebrandt P. Prognostic threshold levels of NT-proBNP testing in primary care. Eur Heart J. 2009;30: 66-73.
Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J. 2006;151:999-1005.
Hildebrandt P, Collinson PO, Doughty RN, Fuat A. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cutpoint for ruling out suspected systolic dysfunction in primary care. Eur Heart J. 2010;31:1881-89.
Castellanos LR, Bhalla V, Isakson S, Daniels LB, Bhalla MA, Lin JP, et al. B-type natriuretic peptide and impedance cardiography at the time of routine echocardiography predict subsequent heart failure events. J Card Fail. 2009;15 (1):41-7.
Noveanu M, Pargger H, Breidthardt T, Reichlin T, Schindler C. Use of B-type natriuretic peptide in the management of hypoxaemic respiratory failure. European Journal of Heart. 2011;13:154-62.
Prontera C. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med. 2004;42:37-44.
Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824-39.
Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes AW. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. J Card Fail. 2011;17:729-34.
Kelder JC, Cowie MR, McDonagh TA, Hardman SM, Grobbee DE, Cost B, Hoes AW. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart. 2011;97:959-63.
Januzzi JL, Van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330-37.
Bayes-Genis A, Pascual-Figal D, Fabregat J. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. Int J Cardiol 2007;120:338-43.
Albers S. Clin Chem Lab Med. 2006;44(1):80-5.
Maisel A. Natriuretic peptide-guided therapy for heart failure: ready for “battle” or too “scarred” by the challenges of trial design?. J Am Coll Cardiol. 2009;55:61-4.
Prontera C, Zaninotto M, Giovannini S, Zucchelli GC, Pilo A, Sciacovelli L, et al. Proficiency testing project for brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) immunoassays: the CardioOrmocheck study. Clin Chem Lab Med. 2009;47:762-68.
Hunt PJ. Immunoreactive amino terminal pro-brain natriuretic. Clin Endocrinol. 1997;47(3):287-96.
Roche Diagnostics. Propéptido natriurético de tipo B N-terminal: proBNP II. Catálogo de Analizadores Elecsys y Cobas. 2011;190 (6):3.
Januzzi JL, Van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330-37.
Lokuge A, Lam L, Cameron P, Krum H, De Villiers S, Bystrzycki A, et al. B-type natriuretic peptide testing and the accuracy of heart failure diagnosis in the emergency department. Circ Heart Fail. 2010;3:104-10.
Grupo de Trabajo de Diagnóstico y Tratamiento de la Insuficiencia Cardiaca Aguda y Crónica 2012 de la Sociedad Europea de Cardiología, Asociación de Insuficiencia Cardiaca (ICA) de la ESC. Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Rev Esp Cardiol. 2012;65,10:938.e1- e59.
Barreiro FJ, Marcos JV, Molina RG, Sastre JF. Algoritmos. Guías prácticas de uso clínico para la solicitud de pruebas [CD-ROM]. Roche Diagnostics: s.l; 2008.
Ketchum ES, Levy WC. Establishing prognosis in heart failure: a multimarker approach. Prog Cardiovasc Dis. 2011;54:86-96.
The European Society of cardiology, Struthers AD. How to use natriuretic peptide levels for diagnosis and prognosis. Eur Heart J. 1999;20:1374-75.
Hunt PJ, Richards AM, Nicholls MG. Immunoreactive aminoterminal pro-brain natriuretic peptide (NT-PROBNP): a new marker for cardiac impairment. Clin Endocrinol. 1997;47:287-96.
Talwar S, Squire IB, Davies JE. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur Heart J. 1999;20:1736-44.
De Lemos JA, Hildebrandt P. Amino-terminal pro-B-type natriuretic peptides: testing in general populations. Am J Cardiol. 2008;101:16-20.
Fisher C. NT proBNP Predicts Prognosis in Patients with Chronic Heart Failure. Heart. 2003;89:879-81.
Gerard CM, Linssen R, Stephan JL. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J. 2010;31:120-27.
Simon DR, Witte K, Ghosh J, Nikitin N. N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population. Eur Heart Journal. 2006;27:447-53.
Pfisterer M, Buser P, Rickli H. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIMECHF) randomized trial. JAMA 2009;301:383-92.
James SK. NT proBNP and other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients with Unstable Coronary Artery Disease. GUSTO IV Substudy. Circulation. 2003,108:275-81.
Anderson B, Sawyer DB. Predicting and preventing the cardiotoxicity of cancer therapy. Expert Rev Cardiovasc Ther. 2008;6(7):1023-33.
Núñez J, Sanchis J, Bodi V, Fonarow GC, Núñez E. Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur. Heart Journal. 2010;31:1752-63.
Korse CM, Taal BG, De Groot CA, Bakker RH, Bonfrer JM. Chromogranin-A and N-Terminal Pro-Brain Natriuretic Peptide: An Excellent Pair of Biomarkers for Diagnostics in Patients With Neuroendocrine Tumor. JCO. 2009;27(26):4293-99.
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2013 Niovis Maceo Montesino, Madelin Rives Figueredo, Yusdaidy Pérez García , Lisett Meriño Collazo
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
